BOOK
Imaging in Gynecologic Oncology, An Issue of PET Clinics, E-Book
Drew A. Torigian | Domenico Rubello
(2018)
Additional Information
Book Details
Abstract
This issue of PET Clinics focuses on Imaging in Gynecologic Oncology, and is edited by Drs. Drew Torigian and Domenico Rubello. Articles will include: The role of CT and MRI in gynecologic oncology; The utility of ultrasonography in gynecologic oncology; FDG-PET assessment of cervical cancer; FDG-PET assessment of ovarian cancer; FDG-PET assessment of other gynecologic cancers; The role of PET imaging in gynecologic radiation oncology; The utility of non-FDG PET in gynecologic oncology; Normal variants and pitfalls encountered in PET assessment of gynecologic malignancies; The role and future of quantitative imaging assessment in gynecologic oncology; Emerging molecular imaging techniques in gynecologic oncology; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Imaging in Gynecologic Oncology\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface: Imaging in Gynecologic Oncology | vii | ||
| The Role of Computed Tomography and Magnetic Resonance Imaging in Gynecologic Oncology | vii | ||
| The Usefulness of Ultrasound Imaging in Gynecologic Oncology | vii | ||
| [18F]-2-Fluoro-2-Deoxy-d-Glucose–PET Assessment of Cervical Cancer | vii | ||
| Fludeoxyglucose F 18 PET/CT Assessment of Ovarian Cancer | vii | ||
| FDG-PET Assessment of Other Gynecologic Cancers | viii | ||
| The Role of PET Imaging in Gynecologic Radiation Oncology | viii | ||
| Non–18F-2-Fluoro-2-Deoxy-d-Glucose PET/Computed Tomography in Gynecologic Oncology: An Overview of Current Status and Futur ... | viii | ||
| Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies | viii | ||
| Quantitative Assessment of Gynecologic Malignancies | ix | ||
| Emerging Molecular Imaging Techniques in Gynecologic Oncology | ix | ||
| PET CLINICS\r | x | ||
| FORTHCOMING ISSUES | x | ||
| July 2018 | x | ||
| October 2018 | x | ||
| January 2019 | x | ||
| RECENT ISSUES | x | ||
| January 2018 | x | ||
| October 2017 | x | ||
| July 2017 | x | ||
| CME Accreditation Page | xi | ||
| PROGRAM OBJECTIVE | xi | ||
| TARGET AUDIENCE | xi | ||
| LEARNING OBJECTIVES | xi | ||
| ACCREDITATION | xi | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | xi | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | xi | ||
| TO ENROLL | xi | ||
| METHOD OF PARTICIPATION | xi | ||
| CME INQUIRIES/SPECIAL NEEDS | xi | ||
| Preface: Imaging in Gynecologic Oncology\r | xiii | ||
| The Role of Computed Tomography and Magnetic Resonance Imaging in Gynecologic Oncology | 127 | ||
| Key points | 127 | ||
| IMAGING RECOMMENDATIONS AND GUIDELINES | 127 | ||
| ENDOMETRIAL CANCER | 128 | ||
| Introduction | 128 | ||
| Staging and Treatment | 128 | ||
| Imaging | 128 | ||
| Stages I to IIIB | 129 | ||
| Stages IIIC to IV | 129 | ||
| UTERINE SARCOMA | 129 | ||
| Introduction | 129 | ||
| Staging and Treatment | 129 | ||
| Imaging | 130 | ||
| CERVICAL CANCER | 131 | ||
| Introduction | 131 | ||
| Staging and Treatment | 131 | ||
| Imaging | 131 | ||
| Stages 0 to I | 132 | ||
| Stage II | 133 | ||
| Stage III | 133 | ||
| Stage IV | 133 | ||
| Lymph node involvement | 133 | ||
| OVARIAN/FALLOPIAN TUBE/PRIMARY PERITONEAL CANCER | 133 | ||
| Introduction | 133 | ||
| Staging and Treatment | 134 | ||
| Imaging | 135 | ||
| Stage I | 135 | ||
| Stages II to III | 135 | ||
| Stage IV | 136 | ||
| Ovarian metastases | 136 | ||
| VULVAR CANCER | 137 | ||
| VAGINAL CANCER | 137 | ||
| MUCOSAL MELANOMA | 138 | ||
| LYMPHOMA | 139 | ||
| GESTATIONAL TROPHOBLASTIC NEOPLASM | 139 | ||
| Introduction | 139 | ||
| Staging and Treatment | 139 | ||
| Imaging | 139 | ||
| REFERENCES | 140 | ||
| The Usefulness of Ultrasound Imaging in Gynecologic Oncology | 143 | ||
| Key points | 143 | ||
| INTRODUCTION | 143 | ||
| IMAGING TECHNIQUE AND NORMAL ANATOMY | 143 | ||
| Imaging Technique | 143 | ||
| Gray scale ultrasound imaging | 144 | ||
| Spectral Doppler ultrasound imaging | 144 | ||
| Sonohysterography | 144 | ||
| Normal Anatomy | 145 | ||
| Uterus | 145 | ||
| Ovary | 145 | ||
| IMAGING FINDINGS AND PATHOLOGY | 146 | ||
| Uterus | 146 | ||
| Myometrial pathology | 146 | ||
| Leiomyoma | 146 | ||
| Uterine sarcoma | 146 | ||
| Endometrial pathology | 147 | ||
| Hyperplasia | 148 | ||
| Polyps | 148 | ||
| Carcinoma | 148 | ||
| Cervical pathology | 149 | ||
| Polyps | 149 | ||
| Carcinoma | 149 | ||
| Ovary | 150 | ||
| Ovarian cysts | 150 | ||
| Simple and probably benign cysts | 151 | ||
| Hemorrhagic cyst | 152 | ||
| Endometrioma | 153 | ||
| Ovarian neoplasms | 153 | ||
| Epithelial neoplasm | 154 | ||
| Germ cell neoplasms | 154 | ||
| Sex cord-stromal cell tumors | 155 | ||
| Metastasis | 156 | ||
| Fallopian Tube | 156 | ||
| Gestational Trophoblastic Disease | 156 | ||
| Complete and partial moles | 157 | ||
| Gestational trophoblastic neoplasia | 158 | ||
| SUMMARY | 159 | ||
| REFERENCES | 160 | ||
| [18F]-2-Fluoro-2-Deoxy-D-glucose–PET Assessment of Cervical Cancer | 165 | ||
| Key points | 165 | ||
| INTRODUCTION | 165 | ||
| DETECTION | 165 | ||
| PATHOLOGY | 166 | ||
| STAGING | 166 | ||
| ANATOMIC IMAGING | 166 | ||
| tcaps | 166 | ||
| PROTOCOLS | 166 | ||
| STAGING | 167 | ||
| Primary Tumor | 167 | ||
| Lymph Node Metastases | 168 | ||
| Distal Metastatic Disease | 169 | ||
| TREATMENT PLANNING | 169 | ||
| External Beam Radiation Therapy | 169 | ||
| Brachytherapy | 170 | ||
| Evidence | 170 | ||
| FOLLOW-UP EVALUATION | 171 | ||
| Response Assessment | 171 | ||
| Recurrence/Restaging | 172 | ||
| PET/COMPUTED TOMOGRAPHY PITFALLS | 173 | ||
| Benign Conditions | 173 | ||
| Post-Therapy Changes | 173 | ||
| TUMOR HYPOXIA | 173 | ||
| MR IMAGING | 173 | ||
| SUMMARY | 174 | ||
| REFERENCES | 175 | ||
| Fludeoxyglucose F 18 PET/CT Assessment of Ovarian Cancer | 179 | ||
| Key points | 179 | ||
| INTRODUCTION | 179 | ||
| EPIDEMIOLOGY OF OVARIAN CANCER | 179 | ||
| SPREAD | 180 | ||
| STAGING: INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS, TNM, AND WORLD HEALTH ORGANIZATION CLASSIFICATIONS | 180 | ||
| International Federation of Gynecology and Obstetrics Classification | 180 | ||
| Stage I | 180 | ||
| Stage II | 181 | ||
| Stage III | 181 | ||
| Stage IV | 181 | ||
| TNM Classification According to the American Joint Committee on Cancer | 181 | ||
| Primary tumor | 181 | ||
| Regional lymph node | 181 | ||
| Distant metastasis | 181 | ||
| Histopathologic Classification (World Health Organization and American Joint Committee on Cancer) | 181 | ||
| IMAGING PROCEDURES | 183 | ||
| THE ROLE OF CANCER ANTIGEN 125 IN DIAGNOSIS OF OVARIAN CANCER | 184 | ||
| F 18 PET/CT | 184 | ||
| Conventional Imaging | 184 | ||
| Fludeoxyglucose F 18 PET/CT | 186 | ||
| THE ROLE OF FLUDEOXYGLUCOSE F 18 PET/CT IN STAGING OVARIAN CANCER | 187 | ||
| THE PROGNOSTIC VALUE OF FLUDEOXYGLUCOSE F 18 PET/CT IN PRIMARY OVARIAN CANCER AND IN PREDICTING RESPONSE TO NEOADJUVANT CHE ... | 190 | ||
| THE ROLE OF FLUDEOXYGLUCOSE F 18 PET/CT IN RECURRENT OVARIAN CANCER | 190 | ||
| THE PROGNOSTIC VALUE OF FLUDEOXYGLUCOSE F 18 PET/CT IN RECURRENT OVARIAN CANCER AND IN PREDICTING RESPONSE TO ADJUVANT CHEM ... | 197 | ||
| FLUDEXOYGLUCOSE F 18 PET/MR IMAGING IN ASSESSMENT OF OVARIAN CANCER | 197 | ||
| REFERENCES | 198 | ||
| FDG-PET Assessment of Other Gynecologic Cancers | 203 | ||
| Key points | 203 | ||
| INTRODUCTION | 203 | ||
| IMAGING PROTOCOL | 203 | ||
| ENDOMETRIAL CANCER | 204 | ||
| UTERINE SARCOMAS | 209 | ||
| VULVAR CARCINOMA | 212 | ||
| VAGINAL CANCER | 217 | ||
| SUMMARY | 220 | ||
| REFERENCES | 220 | ||
| The Role of PET Imaging in Gynecologic Radiation Oncology | 225 | ||
| Key points | 225 | ||
| INTRODUCTION | 225 | ||
| UTERINE CANCER | 226 | ||
| OVARIAN CANCER | 227 | ||
| CERVICAL CANCER | 228 | ||
| VULVAR CANCER | 232 | ||
| VAGINAL CANCER | 234 | ||
| SUMMARY | 234 | ||
| REFERENCES | 234 | ||
| Non–18F-2-Fluoro-2-Deoxy-d-Glucose PET/Computed Tomography in Gynecologic Oncology | 239 | ||
| Key points | 239 | ||
| -GLUCOSE PET RADIOTRACERS IN GYNECOLOGIC MALIGNANCIES | 239 | ||
| 18F-2-FLUORO-2-DEOXY-D-GLUCOSE: THE SHORTCOMINGS IN GYNECOLOGIC MALIGNANCIES | 240 | ||
| OVARIAN CANCER | 240 | ||
| THE METABOLIC PHENOTYPES OF EPITHELIAL OVARIAN CARCINOMAS: THE CHOLINIC PHENOTYPE AND THE LIPOGENIC PHENOTYPE | 241 | ||
| CERVICAL CANCER: PRELIMINARY APPLICATION STUDIES WITH 11C-CHOLINE AND 3′-DEOXY-3′-18F-FLUOROTHYMIDINE | 241 | ||
| IN CERVICAL CANCER: SALIENT RESULTS | 243 | ||
| RESPONSE ASSESSMENT IN CERVICAL CANCER | 243 | ||
| PET IN UTERINE MALIGNANCIES: ENDOMETRIAL AND MYOMETRIAL PATHOLOGIES | 243 | ||
| Studies That Explored Both Endometrial and Myometrial Tumors | 243 | ||
| Studies on Non–18F-2-Fluoro-2-Deoxy-d-Glucose PET in Endometrial Pathologies | 244 | ||
| Studies Exploring Non–18F-2-Fluoro-2-Deoxy-d-Glucose PET Radiotracers in Myometrial Tumors: Benign and Malignant Pathologies | 245 | ||
| SUMMARY | 246 | ||
| REFERENCES | 247 | ||
| Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies | 249 | ||
| Key points | 249 | ||
| INTRODUCTION | 249 | ||
| TECHNICAL ASPECTS OF THE SCAN TO BE CONSIDERED | 250 | ||
| NORMAL VARIANTS AND COMMON ARTIFACTS | 252 | ||
| WITH PET | 259 | ||
| SUMMARY | 266 | ||
| REFERENCES | 266 | ||
| Quantitative Assessment of Gynecologic Malignancies | 269 | ||
| Key points | 269 | ||
| INTRODUCTION | 269 | ||
| CERVICAL CANCER | 269 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in the Evaluation of Primary Lesions | 270 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in Distant Metastases | 271 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in Treatment Planning | 272 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in the Assessment of Treatment Response | 272 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in Restaging and Prognostication | 273 | ||
| ENDOMETRIAL CANCER | 276 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in Localized Tumor Evaluation | 276 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in the Detection of Recurrence | 277 | ||
| OVARIAN MALIGNANCIES | 278 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose in the Initial Evaluation | 279 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose for Residual, Recurrent, and Metastatic Disease | 280 | ||
| PET/Computed Tomography with 18F-fluorodeoxyglucose for Response Assessment to Therapy | 281 | ||
| SUMMARY | 282 | ||
| REFERENCES | 282 | ||
| Emerging Molecular Imaging Techniques in Gynecologic Oncology | 289 | ||
| Key points | 289 | ||
| INTRODUCTION | 289 | ||
| MR IMAGING | 290 | ||
| Diffusion-Weighted Imaging Measurements Reflecting Tumor Microstructure | 290 | ||
| Chemical Exchange Saturation Transfer Imaging | 290 | ||
| Dynamic Contrast Enhancement–MR Imaging Parameters Reflecting Tumor Microvasculature | 291 | ||
| MR Imaging with Lymph Node–Specific Contrast Agent | 291 | ||
| Magnetic Resonance Spectroscopy | 291 | ||
| Dynamic Nuclear Polarization | 291 | ||
| PET | 291 | ||
| 18F-Fluorodeoxyglucose PET/Computed Tomographic Applications for Endometrial Cancer | 291 | ||
| 18F-Fluorodeoxyglucose PET/Computed Tomographic Applications for Cervical and Vulvar Cancers | 293 | ||
| Novel PET Radiotracers | 293 | ||
| Applications of PET/MR Imaging in Gynecologic Cancers | 293 | ||
| Radiomics | 295 | ||
| SUMMARY | 295 | ||
| REFERENCES | 296 |